The financing includes $30 million in Series B equity and a $10 million venture debt term sheet, according to a news relese.
The BEAR implant was launched in 2021 and have been used with more than 500 patients, Patrick McBrayer, president and CEO of Miach Orthopaedics, said in the release. The most recent city to add the implant is Buffalo, N.Y. where Peter Gambacorta, DO, completed the debut case.
The BEAR implant uses a patient’s own blood to bridge and repair their ACL.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.